Vext Science : Investor Presentation - June 2024
A growing, profitable cannabis company with operations in Arizona and Ohio All references to currency...
Source: marketscreener.com
📰 Forward Looking Statements News
Page 5 - Forward Looking Statements News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Forward Looking Statements. Real-time updates on events, politics, business and more.
Candel Therapeutics : Corporate Presentation - June 2024
Tipping the balance in favor of the immune system to fight cancer Corporate Presentation | June 2024 NASDAQ: CADL ...
Exchange Commission On While The Company Forward Looking Statements Private Securities Litigation Reform Act Exchange Commission
Source: marketscreener.com
Aerovate Therapeutics : June 2024 Corporate Presentation
Meaningfully Improving the Lives of Patients with Rare Cardiopulmonary Disease Targeting the Hyperproliferative Cause ...
United States Aerovate Therapeutics Inc While The Company Exchange Commission Forward Looking Statements Aerovate Therapeutics
Source: marketscreener.com
Kymera Therapeutics : Corporate Presentation, June 2024
Reinventing Medicine with Protein Degradation June 2024 Forward Looking Statements This presentation...
Source: marketscreener.com
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological...
Source: marketscreener.com
Dupixent (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
31.05.2024 - Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, ...
France General United States Georged Yancopoulos Regeneron Velocimmune Regeneron Velocimmunetechnology Regeneron Genetics Center
Source: wallstreet-online.de
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved...
Source: marketscreener.com
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
Dupixent recommended for EU approval by the CHMP to treat patients with COPD Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3...
Source: marketscreener.com
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
TARRYTOWN, N.Y. and PARIS, May 31, 2024 -- Regeneron Pharmaceuticals, Inc. and Sanofi today announced the U.S. Food and Drug Administration has extended by three months the target action date of...
Source: marketscreener.com